Jasper Therapeutics, Inc. (JSPR) Stock Score, Valuation & Financial Research

Jasper Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for JSPR

Jasper Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.56. These figures are a research snapshot, not a buy or sell recommendation.

What Jasper Therapeutics, Inc. does

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Jasper Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research, development, and clinical testing of its proprietary product candidates, specifically briquilimab, for mast cell-driven diseases.

Products and services

  • The company is developing briquilimab, a humanized monoclonal antibody targeting c-Kit (CD117) to treat mast cell-driven diseases including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma.

Customer types

Patients with mast cell-driven diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business strengths to evaluate

  • Proprietary clinical-stage pipeline focused on mast cell biology Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty regarding clinical trial outcomes and regulatory approval Source
  • Pending shareholder class action and derivative litigation Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

JSPR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.56
Market capitalization:
9.1M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -31.77M
Free cash flow:
USD -77.17M
Cash:
USD 7.31M
Total debt:
USD 270K
EPS:
USD -1.59

What stands out

  • Free cash flow is USD -77.17M, negative for the stored period.
  • The balance sheet shows USD 7.31M of cash versus USD 270K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.04M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for JSPR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can JSPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is JSPR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for JSPR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of JSPR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research JSPR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.